<DOC>
	<DOCNO>NCT00775463</DOCNO>
	<brief_summary>This study evaluate effect treprostinil diethanolamine ( UT-15C ) sustain release tablet ( compare placebo ) digital ulcer patient scleroderma . Treprostinil diethanolamine analog prostacyclin . Prostacyclin naturally occur substance produce cell blood vessel inhibit platelet aggregation , induces vasodilation , suppress smooth muscle proliferation . Improvement blood flow lower limbs finger would anticipate result reduction ischemic pain , Raynaud 's phenomenon promote heal digital ulcer ischemic wound .</brief_summary>
	<brief_title>Digital Ischemic Lesions Scleroderma Treated With Oral Treprostinil Diethanolamine</brief_title>
	<detailed_description />
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Subject give voluntary write informed consent participate study Diagnosis systemic sclerosis ( SSc ) define American College Rheumatology ( ACR ) criteria Males female age great 18 year Screening Presence least one active digital ulcer ( meet protocol define qualification active digital ulcer ) Baseline Females childbearing potential willing use reliable form medically acceptable contraception negative pregnancy test Screening Baseline Able communicate effectively study personnel willing comply protocol requirement Diagnosis pulmonary arterial hypertension ( PAH ) Body weight less 40 kg Screening confirm Baseline History postural hypotension , unexplained syncope , blood pressure le 90 mmHg systolic 50 mmHg diastolic Screening Baseline Hemoglobin concentration le 75 % low limit normal range Screening Moderate severe hepatic impairment , i.e. , ChildPugh Class B C , ALT great three time upper limit normal Intractable diarrhea , severe malabsorption , define great 15 % unintentional loss body weight last 6 month prior Screening ; severe organ failure ( e.g. , lung , kidney ) , bleed diathesis platelet disorder , lifethreatening condition Pregnant breastfeeding Simultaneously fulfil criterion second connective tissue disease include systemic lupus erythermatosus , rheumatoid arthritis inflammatory myopathy Sympathectomy upper limb , involve hand , perform within 12 month Baseline . Sympathectomy perform nontarget limb ( hand present qualify ulcer ) include hand , perform within 6 month Baseline Receipt prostanoid treatment ( epoprostenol , treprostinil sodium , prostacyclin analog ) within previous 3 month Baseline condition include Raynaud 's phenomenon , rest pain / digital ulcer Required systemic antibiotic infect digital ulcer within 2 week Screening Local injection botulinum toxin affect finger within 1 month prior Baseline Treatment endothelin receptor antagonist within 1 month prior Baseline Patients phosphodiasterase inhibitor , sildenafil tadalafil , receive treatment le 6 month prior Baseline ( unless intermittent treatment male erectile dysfunction ) Treatment statin within 1 month prior Screening , unless management hyperlipidemia Received investigational product within 1 month precede Screening Known hypersensitivity treprostinil diethanolamine excipients Tobacco nicotine use level within past 6 month prior Screening Any condition laboratory opinion investigator might interfere subject 's participation , pose additional risk subject , could prevent understand objective , nature consequence trial , compliance protocol , adherence therapy , would interfere interpretation study assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Scleroderma , Diffuse</keyword>
	<keyword>Scleroderma , Limited</keyword>
	<keyword>Scleroderma , Systemic</keyword>
	<keyword>Ulcer</keyword>
	<keyword>prostacyclin</keyword>
</DOC>